Cadila Pharmaceuticals launches Tikacad an anti-platelet drug-containing Ticagrelor for coronary artery disease therapeutics market

The rising prevalence of coronary artery disease is a prime factor driving the growth of the coronary artery disease therapeutics market. According to the World Health Organization, cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Out of the 17 million premature deaths (under the age of 70) due to noncommunicable diseases in 2019, 38% were caused by CVDs. High blood pressure, diabetes or insulin resistance, high cholesterol, sedentary lifestyle, and hypertension are some of the factors that caused coronary artery disease.

Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1799

In October 2020, Cadila Pharmaceuticals launches Tikacad in India, an anti-platelet drug-containing Ticagrelor, a P2Y12 platelet inhibitor indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with the acute coronary syndrome (ACS)

In June 2020, AstraZeneca has received approval from the US Food and Drug Administration (FDA) for Brilinta (ticagrelor) to decrease the risk of a first heart attack or stroke in high-risk patients suffering from coronary artery disease (CAD)

In January 2021, Merck known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved VERQUVO, a soluble guanylate cyclase (sGC) stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization

North America is expected to hold the dominant position in the global coronary artery disease therapeutics market and this is accredited to the increasing FDA approval for the launch of a new drug for coronary artery disease. For instance, in December 2019, the U.S. Food and Drug Administration today approved the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels (a type of fat in the blood) of 150 milligrams per deciliter or higher.

Coronary Artery Disease (CAD), is a medical condition in which fatty deposits (fat streaks or plaques) build up along the interior walls of coronary arteries. Coronary arteries are also the largest blood vessels that supply body with oxygen, nutrients, and blood. Also referred to as hardening and atherosclerosis of the arteries, coronary artery disease or CAD is the leading cause of heart attacks and strokes in people of all ages. The risk for developing coronary artery disease or CAD is hereditary, but there are other factors that put at a greater risk for coronary artery disease. One such factor is being overweight or obese.

Key players operating in coronary artery disease therapeutics market include Astra Zeneca, Gilead, Novartis, Pfizer, Bayer, Merck & Co, Glaxo Smith Kline, and Mylan N.V.

LIMITED TIME OFFER – Hurry Up!
Exclusive offer!!! Purchase the report at a discounted rate!!!

Buy Now with Discount for Premium Report (Flat US $ 2000 Off) : https://www.coherentmarketinsights.com/promo/buynow/1799

Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.